Actionable news
All posts from Actionable news
Actionable news in INCY: Incyte Corporation,

Entry Into a Material Definitive

Effective March31, 2016,Incyte Corporation (Incyte) and Eli Lilly and Company (Lilly) entered into an amendment (the Lilly Amendment) to the License, Development and Commercialization Agreement, entered into as of December18, 2009, and as previously amended, between Incyte and Lilly (the Lilly License Agreement). The Lilly Amendment amends Incytes non-compete obligations under the Lilly License Agreement to allow Incyte to engage in the development and commercialization of ruxolitinib in the graft-versus-host disease (GVHD) field. Incyte has agreed to make an upfront payment to Lilly of $35 million and Lilly is eligible to receive future additional payments if defined regulatory milestones relating to ruxolitinib for GVHD are achieved. Incyte has also waived its baricitin ib co-promotion option under the Lilly License...